tetano
Editor, Senior Moderator
Front Immunol
. 2022 Mar 17;13:851497.
doi: 10.3389/fimmu.2022.851497. eCollection 2022.
Plasma Markers of Neutrophil Extracellular Trap Are Linked to Survival but Not to Pulmonary Embolism in COVID-19-Related ARDS Patients
Renaud Prével[SUP] 1 2 [/SUP], Annabelle Dupont[SUP] 3 [/SUP], Sylvie Labrouche-Colomer[SUP] 4 5 [/SUP], Geoffrey Garcia[SUP] 6 [/SUP], Antoine Dewitte[SUP] 7 8 [/SUP], Antoine Rauch[SUP] 3 [/SUP], Julien Goutay[SUP] 9 [/SUP], Morgan Caplan[SUP] 9 [/SUP], Elsa Jozefowicz[SUP] 10 [/SUP], Jean-Philippe Lanoix[SUP] 11 12 [/SUP], Julien Poissy[SUP] 13 [/SUP], Etienne Rivière[SUP] 4 14 [/SUP], Arthur Orieux[SUP] 1 [/SUP], Denis Malvy[SUP] 15 [/SUP], Didier Gruson[SUP] 1 2 [/SUP], Loic Garçon[SUP] 6 [/SUP], Sophie Susen[SUP] 3 [/SUP], Chloé James[SUP] 4 5 [/SUP]
Affiliations
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) can cause life-threatening acute respiratory distress syndrome (ARDS). Recent data suggest a role for neutrophil extracellular traps (NETs) in COVID-19-related lung damage partly due to microthrombus formation. Besides, pulmonary embolism (PE) is frequent in severe COVID-19 patients, suggesting that immunothrombosis could also be responsible for increased PE occurrence in these patients. Here, we evaluate whether plasma levels of NET markers measured shorty after admission of hospitalized COVID-19 patients are associated with clinical outcomes in terms of clinical worsening, survival, and PE occurrence.
Patients and methods: Ninety-six hospitalized COVID-19 patients were included, 50 with ARDS (severe disease) and 46 with moderate disease. We collected plasma early after admission and measured 3 NET markers: total DNA, myeloperoxidase (MPO)-DNA complexes, and citrullinated histone H3. Comparisons between survivors and non-survivors and patients developing PE and those not developing PE were assessed by Mann-Whitney test.
Results: Analysis in the whole population of hospitalized COVID-19 patients revealed increased circulating biomarkers of NETs in patients who will die from COVID-19 and in patients who will subsequently develop PE. Restriction of our analysis in the most severe patients, i.e., the ones who enter the hospital for COVID-19-related ARDS, confirmed the link between NET biomarker levels and survival but not PE occurrence.
Conclusion: Our results strongly reinforce the hypothesis that NETosis is an attractive therapeutic target to prevent COVID-19 progression but that it does not seem to be linked to PE occurrence in patients hospitalized with COVID-19.
Keywords: COVID-19; acute respiratory distress syndrome; immunothrombosis; neutrophil extracellular trap; pulmonary embolism.
. 2022 Mar 17;13:851497.
doi: 10.3389/fimmu.2022.851497. eCollection 2022.
Plasma Markers of Neutrophil Extracellular Trap Are Linked to Survival but Not to Pulmonary Embolism in COVID-19-Related ARDS Patients
Renaud Prével[SUP] 1 2 [/SUP], Annabelle Dupont[SUP] 3 [/SUP], Sylvie Labrouche-Colomer[SUP] 4 5 [/SUP], Geoffrey Garcia[SUP] 6 [/SUP], Antoine Dewitte[SUP] 7 8 [/SUP], Antoine Rauch[SUP] 3 [/SUP], Julien Goutay[SUP] 9 [/SUP], Morgan Caplan[SUP] 9 [/SUP], Elsa Jozefowicz[SUP] 10 [/SUP], Jean-Philippe Lanoix[SUP] 11 12 [/SUP], Julien Poissy[SUP] 13 [/SUP], Etienne Rivière[SUP] 4 14 [/SUP], Arthur Orieux[SUP] 1 [/SUP], Denis Malvy[SUP] 15 [/SUP], Didier Gruson[SUP] 1 2 [/SUP], Loic Garçon[SUP] 6 [/SUP], Sophie Susen[SUP] 3 [/SUP], Chloé James[SUP] 4 5 [/SUP]
Affiliations
- PMID: 35371025
- PMCID: PMC8968169
- DOI: 10.3389/fimmu.2022.851497
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) can cause life-threatening acute respiratory distress syndrome (ARDS). Recent data suggest a role for neutrophil extracellular traps (NETs) in COVID-19-related lung damage partly due to microthrombus formation. Besides, pulmonary embolism (PE) is frequent in severe COVID-19 patients, suggesting that immunothrombosis could also be responsible for increased PE occurrence in these patients. Here, we evaluate whether plasma levels of NET markers measured shorty after admission of hospitalized COVID-19 patients are associated with clinical outcomes in terms of clinical worsening, survival, and PE occurrence.
Patients and methods: Ninety-six hospitalized COVID-19 patients were included, 50 with ARDS (severe disease) and 46 with moderate disease. We collected plasma early after admission and measured 3 NET markers: total DNA, myeloperoxidase (MPO)-DNA complexes, and citrullinated histone H3. Comparisons between survivors and non-survivors and patients developing PE and those not developing PE were assessed by Mann-Whitney test.
Results: Analysis in the whole population of hospitalized COVID-19 patients revealed increased circulating biomarkers of NETs in patients who will die from COVID-19 and in patients who will subsequently develop PE. Restriction of our analysis in the most severe patients, i.e., the ones who enter the hospital for COVID-19-related ARDS, confirmed the link between NET biomarker levels and survival but not PE occurrence.
Conclusion: Our results strongly reinforce the hypothesis that NETosis is an attractive therapeutic target to prevent COVID-19 progression but that it does not seem to be linked to PE occurrence in patients hospitalized with COVID-19.
Keywords: COVID-19; acute respiratory distress syndrome; immunothrombosis; neutrophil extracellular trap; pulmonary embolism.